NSPR InspireMD, Inc. Insider Trading

Director Paul Stuka buys 20,000 NSPR shares at $0.88; stock down 68.6% from 52-week high, prior buys at this ticker underperformed.

Paul Stuka, a director at InspireMD, purchased 20,000 shares at $0.88 on 2026-05-27, bringing his holdings to 667,871 shares (a 3.1% increase). The purchase occurred at a stock price significantly depressed from its 52-week high of $2.93, and the stock has declined 48.3% over the past 90 days and 19.3% over the past 30 days. However, Stuka's prior trades at NSPR (5 total before this transaction) show a consistent pattern of poor outcomes: his most recent four purchases, on 2026-05-14, 2026-05-13, 2026-05-11, and 2026-05-08, all posted negative 90-day returns ranging from -21.7% to -24.4%, with zero of the five prior NSPR trades being well-timed at the 90-day mark. The company is unprofitable (net income of $-13.7M on quarterly revenue of $3.4M) despite 28.1% annual revenue growth, which compounds the signal uncertainty. This purchase in the context of recent repeated buys during a sustained decline warrants monitoring but does not suggest a compelling directional signal given the track record at this ticker.

Director Stuka Paul bought 15,000 shares at $1.16 average; stock down -40.0% in 90 days, cluster pattern with 3 other insiders

Stuka Paul, Director at InspireMD (NSPR), executed 2 separate purchases totaling 15,000 shares for $17,325.00 at a blended average price of $1.16 on May 13–14, 2026. This transaction occurs within a broader cluster pattern: 3 other insiders also bought within the past 14 days. However, the timing context raises questions about execution discipline. The stock has declined -40.0% over the past 90 days and currently trades at $1.05, -64.2% below its 52-week high of $2.93. Reviewing his same-ticker history at NSPR, all 5 prior purchases at this ticker show negative 90-day returns (ranging from -1.7% to -13.0%), and none of those prior buys proved well-timed. The company remains unprofitable with net income of $-13.7M despite quarterly revenue of $3.4M, adding fundamental headwinds to the timing question.

CEO Slosman doubles down with second open-market purchase in 10 months as stock trades well below 52-week highs amid unprofitable fundamentals.

CEO and President Marvin Slosman is making his second open-market purchase at InspireMD in less than a year, acquiring shares at levels well below the company's 52-week highs. The stock has declined significantly over both the prior month and quarter, trading near the lower end of its 52-week range, yet Slosman is committed enough to add to his position. His prior open-market purchase last year was well-timed in the near term, though the longer-term outcome proved negative; this current buy at even lower prices occurs while the company remains unprofitable with recent quarterly losses, though revenue is growing. The timing is notable: three other insiders purchased shares within the same two-week window, creating a cluster of insider buying pressure on the same stock during a period of weakness. For a CEO to keep buying into a distressed valuation and declining stock suggests either conviction in a turnaround or simply opportunistic accumulation at depressed prices.

Director Stuka Paul acquired 75,626 shares in two open-market purchases; part of three-insider buying cluster amid stock down from 52-week highs.

Stuka Paul, a director of InspireMD, acquired over 75,000 shares in two purchases within a three-day window as part of a broader wave of insider buying by three directors. The stock is trading well below its 52-week high and has declined significantly over the past quarter, creating a backdrop of depressed valuation. Paul's own prior buying at this company shows conflicting results: his purchases were well-timed over the near term on three of five occasions, but all five of his prior purchases were underwater over the longer 90-day horizon, suggesting his timing at this stock has been persistently poor. The company remains unprofitable with declining revenue, adding execution risk to the thesis that the current price represents a compelling entry point. This is Paul's eighth and ninth open-market purchase in the 36-month window, reflecting consistent share accumulation despite a track record of timing challenges at this specific stock.

Director Ward Scott R. makes first open-market purchases of 89,250 shares in NSPR, coinciding with broader insider buying wave and depressed stock price.

Ward Scott R., a director at InspireMD, has made his first open-market share purchases in the company, committing personal capital to acquire nearly 90,000 shares across two trades. This move is significant because his prior Form 4 activity consisted entirely of stock-based compensation—this is the first time he has voluntarily written a check to buy shares. The timing coincides with a broader insider buying window where three directors or officers bought shares within a two-week span, suggesting aligned conviction at the board level. The stock is trading sharply below its highs and has declined meaningfully over the past quarter, so this director is buying into clear weakness. However, InspireMD faces fundamental headwinds: the company is unprofitable with revenue contracting and substantial operating losses, creating tension between the insider's purchase conviction and the company's financial trajectory. The director's willingness to deploy personal capital into a depressed, fundamentally challenged asset warrants close monitoring of what operational or strategic shifts may have prompted this first-time open-market buying activity.

Director Gary Roubin buys 90,000 shares of unprofitable biotech stock trading well below recent highs.

Gary Roubin, a director at InspireMD, purchased a substantial stake in the company as it trades significantly below its recent highs and faces mounting losses. This is his third open-market purchase within roughly two years, continuing a pattern of accumulation at this ticker. His most recent prior buy at this company gained value in the near term but declined over a longer horizon, and the current purchase comes at even lower prices—suggesting he continues to see opportunity despite the stock's downward pressure. However, the company's financial fundamentals are deeply challenged: it is unprofitable with shrinking revenue, and the stock has fallen sharply over recent months, indicating either a turnaround bet by a director with inside knowledge or a contrarian accumulation in a struggling business. The mixed outcome from his prior purchase—gains that reversed into losses—underscores the risk profile of this trade.

Director Stuka Paul buys 5,073 shares of NSPR at $1.81; 3 consecutive purchases in 5 days as stock rebounds +19.6% (30-day).

Stuka Paul, a Director, purchased 5,073 shares at $1.81 on December 9, 2025, bringing his holdings to 391,628 shares. This represents his third consecutive buy within a 5-day window (prior purchases on December 5 and December 4), a pattern suggesting sustained accumulation during recent weakness. The stock currently trades at $1.95, having risen +19.6% over the prior 30 days but remains -47.3% below its 52-week high of $3.70. While his cross-ticker track record shows a 50.00% win rate on prior buys at the 90-day horizon (5 buys, +44.6% average 90d return), his prior transaction history at NSPR itself is mixed: one 2025 buy shows +0.8% at 30 days (outcome pending at 90 days), and an earlier 2023 buy delivered +96.6% at 90 days, but a 2025-07-30 purchase returned -7.4% at 90 days. The company posted quarterly revenue of $2,523,000.00 against a net loss of $-12,708,000.00, reflecting persistent unprofitability, though full-year revenue grew +13.0% year-over-year. The repetitive buying during a rebound warrants monitoring to assess whether the stock can sustain its recent momentum or faces further volatility.

Director Stuka Paul bought 5,073 shares of NSPR at $1.86 on 2025-12-05, accumulating position to 388,918 shares amid stock trading -50.8% from 52-week high.

Director Stuka Paul purchased 5,073 shares at $1.86 on 2025-12-05, bringing his total holdings to 388,918 shares—a +1.3% increase on his prior stake. This represents a continuation of buying activity at NSPR, following purchases on 2025-12-04 and 2025-11-12 whose performance cannot yet be measured. The current stock price of $1.82 is -50.8% from the 52-week high of $3.70, and his prior trades at this ticker show mixed timing: a 2025-07-30 buy returned -7.4% over 90 days, while a 2023-05-12 buy returned +96.6%—with only 1 of 2 measurable prior buys being well-timed. The company carries significant structural headwinds: reported revenue of $2,523,000.00 in the latest quarter against net income of $-12,708,000.00, though annual revenue grew +13.0%. His cross-ticker track record shows 4 prior buys with an average 90-day return of +44.6%, but that broader pattern does not address performance specifically at NSPR, where near-term outcomes remain unmeasurable.

Director Stuka Paul bought 10,130 shares of NSPR at $1.85 on 2025-12-04; stock down -22.3% in 90 days, -49.2% from 52-week high.

Director Stuka Paul purchased 10,130 shares at $1.85, increasing his holdings by +2.7% to 383,845 shares. The timing occurs in a weak price environment: the stock trades at $1.88, down -22.3% over the past 90 days and -49.2% below its 52-week high of $3.70. Prior trades at NSPR show mixed results—a 2023 buy achieved +96.6% returns over 90 days, but a 2025-07-30 buy returned only +0.8% at 30 days and -7.4% at 90 days, indicating limited predictive value for this insider's timing at this ticker. The company remains unprofitable with a net income of $-12,708,000 on recent quarterly revenue of $2,523,000. This purchase occurs amid material price weakness and prior timing inconsistency at this security, warranting monitoring of whether the director's view diverges from the broader market decline.

Director Paul Stuka bought 13,431 shares of NSPR at $1.62; stock down -25.2% in 90 days, holds $79.2M cap unprofitable biomedical firm.

Stuka Paul, a Director, purchased 13,431 shares at $1.62 on 2025-11-12, increasing holdings from 360,284 to 373,715 shares. The timing context is challenging: the stock has declined -25.2% over the past 90 days and -49.5% from its 52-week high of $3.70, currently trading at $1.87. Reviewing his same-ticker history at NSPR, his prior buy on 2025-07-30 showed a 90-day return of -7.4%, indicating this repeat purchase arrives as the stock remains under pressure. InspireMD is a small-cap medical device company ($79.2M market cap) that reported a net loss of $12.7M on quarterly revenue of $2.5M and remains unprofitable on a full-year basis, despite 13.0% annual revenue growth. The accumulation of additional shares by an insider during a sustained decline and ongoing losses warrants review of underlying fundamentals and strategy.